ArticleBMJ open diabetes research & care2026
Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRandomized controlled trials and real-world studies have demonstrated that automated insulin delivery (AID) systems enhance glycemic control and mitigate hypoglycemia risk in individuals with type 1 diabetes. This study evaluated the safety, effectiveness, and usability of the twiist AID System on glycemic outcomes in adults with type 1 diabetes. RESEARCH DESIGN AND
methodsThis 8-week, prospective, single-center, single-arm study included 20 adults with type 1 diabetes. The primary outcome measures were the percent of time spent in established continuous glucose monitoring (CGM) glycemic target ranges at 8 weeks. The primary efficacy outcome was percent time in range (%TIR; 70-180 mg/dL) at 8 weeks. Secondary outcomes were the change in glucose pre-occlusion detection; the effects of total daily insulin delivery (TDD) on glucose pre- and post-occlusion detection; the effect of Max basal ratio on %TIR; the effect of users' correction range on %TIR; and change in glycated haemoglobin (HbA1c). Changes in TDD and body weight were also assessed.
results19 participants completed the study. At 8 weeks, the mean %TIR was 70.3±15.5%. Participants achieved or maintained glycemic targets for all CGM metrics except time above >250 mg/dL. A total of 67 occlusion events occurred in 15 participants. These events were detected within 30 min of rising glucose. Higher max basal ratio settings were associated with higher %TIR. The %TIR for participants with a correction range <100 mg/dL was 79.2±13.4% vs 67.2±15.0% for those with a correction range >100 mg/dL. HbA1c levels decreased (-0.4%±0.5%) in participants with baseline HbA1c >7%. A slight increase in TDD (1.3±16.2 U) and a decrease in body weight (-0.09±2.9 kg) were observed. No serious adverse events were reported.
conclusionsEight-week use of twiist enabled participants to achieve or maintain established glycemic targets and suggests the system's ability to detect occlusions before clinically significant glucose rise regardless of TDD. Larger and longer term studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.